Clinical Trial

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.
Protocol Amendment History 12 changes
notable Trial sites expanded: 211 -> 214 locations 2026-07-10
notable Trial sites expanded: 205 -> 211 locations 2026-07-02
notable Trial sites expanded: 188 -> 205 locations 2026-06-24
notable Trial sites expanded: 180 -> 188 locations 2026-06-11
notable Trial sites expanded: 153 -> 180 locations 2026-06-06
notable Trial sites expanded: 135 -> 153 locations 2026-05-29
notable Trial sites expanded: 129 -> 135 locations 2026-05-21
notable Trial sites expanded: 125 -> 129 locations 2026-05-13
notable Trial sites expanded: 114 -> 125 locations 2026-05-06
notable Trial sites expanded: 101 -> 114 locations 2026-04-28
notable Trial sites expanded: 98 -> 101 locations 2026-04-09
notable Trial sites expanded: 91 -> 98 locations 2026-04-01
Trial Details
NCT Number NCT06989437
Lead Sponsor Pfizer
Conditions Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment 982 participants
Start Date 2025-10-03
Primary Completion 2028-01-17 (estimated)
Study Completion 2029-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-09